TFS Capital’s Tempest Therapeutics TPST Stock Holding History

TFS Capital’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6	Closed	-$27K	–	851
2016 Q4	$27K	Buy	+6	New	+$74.7K	0.01%	707

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

TFS Capital's TPST Position: Q1 2017 in Review

TFS Capital sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 6 shares — an estimated $27K sold.

TFS Capital first reported a position in TPST in Q4 2016 and held it in 1 quarter. The position peaked at $27K in Q4 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

TFS Capital reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 6 Tempest Therapeutics shares in Q1 2017, an estimated $27K.
TFS Capital first reported a position in Tempest Therapeutics in Q4 2016 and held it in 1 quarter.
TFS Capital's Tempest Therapeutics position peaked at $27K in Q4 2016.
63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.